Page 10 - Flipbook
P. 10
Is what we’re treating really high risk?
Gleason 8 Biopsy ≠ RP pathology
MDACC, CCF,
Duke NCBD
JHU
2004-2015 2010-2013
2005-2015
Any downgrading 62% 60% 46%
Clinically Significant
downgrading 29% 26% 15%
(≤3+4)
Gansler et. al. J Urol 2017, Qi et al. Can J Urol 2017
Ranasinghe and Chapin, J Urol 2020
